Anti-Infective Agents

All Drugs and Chemicals

Ribavirin

Antimetabolites

Antiviral Agents

Dose Level: 1 1400 mg po BID Dose Level: 2 1800 mg po BID Dose Level: 3 2200 mg po BID Dose Level: 4 2600 mg po BID Dose Level: 5 3000 mg po BID

Eftihia Cocolakis, PhD

Nessrine Hanna, MSc

Wilson Miller, MD, PhD

The purpose of this study is to learn whether oral Ribavirin is safe and effective in treating patients with solid tumour cancers, that have high levels of the protein eIF4E.

This is a dose escalating, open-label, Phase I/II study of single agent oral ribavirin administered daily in solid tumour cancer patients who have failed standard treatments, overexpress eIF4E, and have easily accessible disease for serial biopsies.

Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients

An Open-label, Dose Escalation Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients Expressing Elevated eIF4E

Jewish General Hospital

Wilson Miller

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients	NCT01309490	Malignant Solid...	Ribavirin	18 Years -	Jewish General Hospital
Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients	NCT01309490	Malignant Solid...	Ribavirin	18 Years -	Jewish General Hospital

Spots Global Cancer Trial Database for high eif4e expression